The scientific rationale for the MumCare study, short for Mum’s cardiovascular health for life, rests on a compelling body of evidence. Pregnancy has been described as a clinically underexploited cardiovascular stress test: the dramatic hemodynamic demands of gestation can expose latent vulnerabilities in a woman’s vascular system years before any symptoms appear. Researchers have proposed two overlapping explanations for the connection between pregnancy complications and later heart disease. One holds that shared risk factors, whether genetic, metabolic or behavioral, predispose women to both conditions. The other suggests that pregnancy complications themselves actively accelerate adverse cardiovascular changes. Work by the Norwegian group supports the latter view, showing that the elevated risk of hypertension within ten years after preeclampsia persists even after adjustment for major traditional cardiovascular risk factors. A recent population-based study from Finland added further weight, concluding that having experienced a hypertensive pregnancy was more important for predicting future cardiovascular disease than a high polygenic risk score for several cardiovascular outcomes.

Gestational diabetes tells a parallel story. The condition now affects roughly one in six births worldwide, and its incidence is rising. Beyond short-term dangers such as preeclampsia and premature birth, women with gestational diabetes face a seven-fold increased risk of progressing to type 2 diabetes within ten years of delivery, and diabetes is itself a well-established driver of cardiovascular disease. Population-based studies from Denmark and Norway have found that one third of women develop hypertension within ten years of a hypertensive pregnancy complication, with the risk highest in the first postpartum years. The implication is stark: standard cardiovascular risk calculators, which are generally unreliable in women under forty and ignore reproductive history altogether, miss precisely the window when prevention would be most effective. Middle age, the researchers argue, is simply too late to begin intensified follow-up.

The clinical guidelines landscape reflects this growing awareness only imperfectly. In response to the American Heart Association’s 2011 recognition of adverse pregnancy outcomes as an independent risk factor for maternal cardiovascular disease, the Global Pregnancy Collaboration proposed pragmatic follow-up suggestions in 2016, and Norway’s 2020 national obstetric guidelines codified a simplified version, recommending cardiovascular check-ups at the general practitioner at three to four months and again at twelve months postpartum. European Society of Cardiology guidance suggests periodic screening for hypertension and diabetes after preeclampsia and gestational diabetes. But many international guidelines, particularly those focused on obstetric management, still lack specific recommendations for postpartum cardiovascular follow-up. More importantly, guidelines alone do not guarantee practice. A Norwegian web survey conducted by the MumCare team found that only thirty-six percent of women who had experienced a hypertensive pregnancy or gestational diabetes reported receiving any preventive cardiovascular follow-up afterwards, and follow-up rates reported in the United States are even lower.

Enter the MumCare app, which its developers describe as the first of its kind worldwide. The application has three main components. The first is educational: short instructional videos on blood pressure measurement and its clinical significance, health information aligned with Norwegian national guidelines, and links to authoritative public websites, all available in both Norwegian and English with subtitles for universal accessibility. The second lets women track their own modifiable cardiovascular risk factors, including blood pressure, fasting and non-fasting blood glucose, weight and physical activity, displayed as longitudinal graphs. The third is a push reminder system that operates on two levels: it prompts users when to take a new blood pressure reading based on their previous track record, and it reminds them to book the nationally recommended follow-up visits with their general practitioner at three to four and twelve months after delivery, using the delivery date the woman enters into the app.

The trial itself is methodically designed. Women at Oslo University Hospital, which runs Norway’s largest obstetric department with about 8,700 deliveries annually, are eligible if they are eighteen or older, are pregnant or no more than four weeks postpartum, and have been diagnosed with a hypertensive disorder of pregnancy or gestational diabetes, or both. Women with preexisting chronic hypertension, pregestational diabetes, or other chronic diseases already requiring cardiovascular follow-up are excluded, as are those facing a language barrier to Norwegian or English. After informed consent, participants are allocated by block randomization to either app access or standard care alone, and those in the intervention arm receive a blood pressure device validated for home use at no cost. The target enrollment is 400 women, a figure calculated to detect a difference in one-year general practitioner follow-up rates of roughly 35 percent in the control group versus 50 percent in the app group, with 80 percent statistical power at a five percent significance level.

The primary outcome is refreshingly pragmatic: whether women attend or book the guideline-recommended cardiovascular follow-up with their general practitioner by one year postpartum, assessed through digital questionnaires and telephone interviews at fourteen months. In Norway, where every resident is assigned a general practitioner through the national Regular General Practitioner Scheme, this visit represents the critical gateway to preventive care, encompassing risk assessment and early detection of preclinical hypertension, dyslipidemia, hyperglycemia and obesity. Secondary outcomes are considerably richer. At fourteen months postpartum, validated questionnaires measure health-related self-management using the Health Education Impact Questionnaire, general self-efficacy, and physical activity via the International Physical Activity Questionnaire, while app users additionally complete the System Usability Scale. Then, between fourteen and eighteen months, participants return to the hospital for a comprehensive clinical evaluation.

That clinical assessment is where the trial’s technical ambition becomes most visible. Researchers will measure blood pressure, body mass index, waist circumference and waist-to-hip ratio, and draw blood for an extensive panel including HbA1c, glucose, total, LDL and HDL cholesterol, triglycerides, apolipoproteins B and A1, and lipoprotein(a), the last of which reflects largely genetic cardiovascular risk. Non-invasive cardiac hemodynamics will be assessed with the USCOM ultrasonic cardiac output monitor, capturing systemic vascular resistance, cardiac output, stroke volume and heart rate. The team will also analyze a suite of cardiovascular biomarkers, including GDF-15, high-sensitivity C-reactive protein, soluble HLA-G, NT-proBNP, pregnancy zone protein and serum amyloid A1, several of which are known to be altered in preeclampsia. Blood samples will additionally be banked for future maternal health research. Semi-structured qualitative interviews with selected participants and, with patient permission, their general practitioners, will probe how the app affected self-management and whether it changed the clinical relationship, feeding directly into the next version of the software.

The researchers are candid about the trial’s limitations. The app currently exists only in Norwegian and English, risking underrepresentation of recently immigrated women, a gap the team hopes to address with future language versions, including Urdu, a step already taken by a previous Norwegian pregnancy app for gestational diabetes. The primary outcome relies partly on self-reported attendance, and the choice of a general practitioner visit as the endpoint is most meaningful in countries with a public, gatekeeper-based health system, though the team argues the app’s content could be adapted to other settings. Low retention and adherence, chronic weaknesses of digital health interventions, are being countered by the push reminder system and the co-creation process in which patient representatives from user organizations shaped the app’s functions and visual design from the start. Registered as NCT05835596 and analyzed by intention to treat, the trial embodies a broader vision: that pregnancy, a moment when women are unusually motivated to protect their own and their children’s health, can become the entry point for lifelong cardiovascular prevention, and that a well-designed app in a young woman’s pocket can bridge the widening gap between hospital obstetrics and community care before the first silent signs of heart disease take hold.

Subject of Research: A randomized controlled trial testing a mobile health app to improve postpartum cardiovascular follow-up after hypertensive pregnancy disorders and gestational diabetes.

Article Title: A mobile health-assisted cardiovascular follow-up after pregnancy complications (MumCare): protocol for a randomized controlled trial

Article References: A mobile health-assisted cardiovascular follow-up after pregnancy complications (MumCare): protocol for a randomized controlled trial. (n.d.). https://doi.org/10.3389/fgwh.2026.1889953

Image Credits: AI Generated

DOI: 10.3389/fgwh.2026.1889953

Keywords: MumCare, mobile health, cardiovascular disease, preeclampsia, gestational diabetes, postpartum care, randomized controlled trial, hypertensive disorders of pregnancy, preventive cardiology, digital health, women's health, blood pressure monitoring